FDA approves two-stage bladder cancer regimen, cutting event risk by 49%
Key Facts
The U.S. Food and Drug Administration on November 13, 2026, approved a regimen combining Imfinzi with enfortumab vedotin before surgery, followed by Imfinzi alone afterward, for certain adults with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based treatment. The FDA said the decision applies to a single, sequential regimen, while AstraZeneca said approval followed the application’s priority review designation. The decision was based on results from the Phase 3 VOLGA trial, presented at the 2026 ESMO Congress and published simultaneously in the New England Journal of Medicine. The regimen provides treatment before radical cystectomy, followed by adjuvant treatment. The FDA reviewed the application under Project Orbis, and issued its decision six weeks before the target date.
In a planned interim analysis of the VOLGA trial, the regimen was associated with a 49% reduction in the risk of disease progression, recurrence, failure to undergo surgery or death compared with radical surgery with or without approved adjuvant treatment. The hazard ratio was 0.51, while median event-free survival had not yet been reached in the regimen group. In the comparator group, the median was 12.1 months. At two years, the estimated proportion of patients alive without an event was 64% with the regimen, versus 45% in the comparator group. These figures reflect a measure that combines several clinical outcomes, including disease recurrence and failure to reach surgery, as well as death.
Overall survival results showed an estimated 42% reduction in the risk of death with the regimen compared with the comparator group, with a hazard ratio of 0.58. Median overall survival had not yet been reached in either group at the time of analysis. The result provides an early estimate of the effect on the risk of death, while the comparison remains based on trial follow-up through the time of analysis. Alongside efficacy measures, safety data showed grade 3 or 4 adverse events, from any cause, in 64% of patients who received the regimen, versus 44% in the comparator group. The FDA said common reactions included elevated liver enzymes, rash, itching, fatigue, diarrhea and peripheral neuropathy.
FDA information warned of immune-mediated reactions that may affect different organs or tissues and can be serious or fatal, as well as infusion-related reactions and fetal risk. The recommended regimen includes 3 cycles of enfortumab vedotin with durvalumab before surgery, followed by durvalumab alone for up to 9 cycles afterward. AstraZeneca said patient-reported quality of life remained preserved after surgery in the regimen group. The VOLGA trial included 695 patients, randomly assigned in a 1:1:1 ratio to 3 treatment arms. The trial was conducted at 182 centers across 25 countries.
The new approval follows a separate U.S. approval of Imfinzi on March 31, 2025, for patients with muscle-invasive bladder cancer, in combination with gemcitabine and cisplatin before surgery and Imfinzi afterward, based on the NIAGARA trial. In that trial, the regimen was associated with a 32% reduction in the risk of disease progression, recurrence, failure to undergo surgery or death compared with preoperative chemotherapy and surgery, and median event-free survival in the comparator group was 46.1 months. Matthew Galsky, a NIAGARA investigator, said, "About half of patients see their cancer return despite chemotherapy and surgery intended to cure them." The regimen approved by the FDA in November differs from the earlier regimen, targeting patients who are ineligible for or refuse cisplatin-based treatment. This means the approval adds a treatment option for a specific group within the same disease.
In trading, EL7 data showed AstraZeneca shares closed at $189.39 on November 9, then $186.76 on November 10 and $185.48 on November 11. The close fell to $184.38 on November 12, before the shares ended the November 13 session at $184.45. The approval-session close was $184.45, according to EL7 data. Available sources do not include an estimate of the approval’s financial impact on company sales or Imfinzi revenue. AstraZeneca said applications seeking approval of the regimen based on VOLGA results remain under review in the European Union, Japan and several other countries.